193 related articles for article (PubMed ID: 10921347)
1. [Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases].
Kuzushima K
Rinsho Ketsueki; 2000 Jun; 41(6):487-90. PubMed ID: 10921347
[No Abstract] [Full Text] [Related]
2. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.
Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P
J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063
[TBL] [Abstract][Full Text] [Related]
3. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
4. [Behavior of antigen-specific CD8+ T cells in Epstein-Barr virus-related disease].
Kuzushima K
Uirusu; 2001 Jun; 51(1):43-9. PubMed ID: 11565264
[No Abstract] [Full Text] [Related]
5. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder.
Kuzushima K; Kimura H; Hoshino Y; Yoshimi A; Tsuge I; Horibe K; Morishima T; Tsurumi T; Kojima S
J Infect Dis; 2000 Sep; 182(3):937-40. PubMed ID: 10950793
[TBL] [Abstract][Full Text] [Related]
6. Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load.
Hoshino Y; Kimura H; Kuzushima K; Tsurumi T; Nemoto K; Kikuta A; Nishiyama Y; Kojima S; Matsuyama T; Morishima T
Bone Marrow Transplant; 2000 Jul; 26(2):199-201. PubMed ID: 10918431
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection.
Sugaya N; Kimura H; Hara S; Hoshino Y; Kojima S; Morishima T; Tsurumi T; Kuzushima K
J Infect Dis; 2004 Sep; 190(5):985-8. PubMed ID: 15295706
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
[TBL] [Abstract][Full Text] [Related]
10. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
Mautner J; Bornkamm GW
Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
[TBL] [Abstract][Full Text] [Related]
11. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
[TBL] [Abstract][Full Text] [Related]
13. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
14. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
15. Search for correlation of CD8 T cell response to Epstein-Barr virus with clinical status in rheumatoid arthritis: a 15 month followup pilot study.
Berthelot JM; Saulquin X; Coste-Burel M; Peyrat MA; Echasserieau K; Bonneville M; Houssaint E
J Rheumatol; 2003 Aug; 30(8):1673-9. PubMed ID: 12913921
[TBL] [Abstract][Full Text] [Related]
16. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.
Guppy AE; Rawlings E; Madrigal JA; Amlot PL; Barber LD
Transplantation; 2007 Dec; 84(11):1534-9. PubMed ID: 18091531
[TBL] [Abstract][Full Text] [Related]
17. Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient.
Piriou ER; van Dort K; Weel JF; Bemelman FJ; Gamadia LE; van Oers MH; van Baarle D
Clin Immunol; 2006 Apr; 119(1):16-20. PubMed ID: 16386961
[TBL] [Abstract][Full Text] [Related]
18. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
[TBL] [Abstract][Full Text] [Related]
19. Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection.
Woodberry T; Suscovich TJ; Henry LM; Davis JK; Frahm N; Walker BD; Scadden DT; Wang F; Brander C
J Infect Dis; 2005 Nov; 192(9):1513-24. PubMed ID: 16206065
[TBL] [Abstract][Full Text] [Related]
20. [Epstein-Barr virus (1)--Establishment of the infection and dynamics of virus--specific T cell responses].
Kuzushima K
Uirusu; 2002 Jun; 52(1):123-7. PubMed ID: 12227160
[No Abstract] [Full Text] [Related]
[Next] [New Search]
